NASDAQ · ODTX
Odyssey Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ODTX: Nov 4, 2026
Odyssey Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.13 | $-0.91 | $-1.39 | 4 |
| Dec 2026 | $-1.13 | $-0.90 | $-1.44 | 5 |
| Mar 2027 | $-1.25 | $-1.00 | $-1.55 | 3 |
| Jun 2027 | $-1.32 | $-1.05 | $-1.66 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Fintel- MarketBeat · Oct 25, 12:02 PM EDTOdyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial ReadoutsOdyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor webcast. The company said the complete induction dataset, b
- RTTNews · Oct 20, 8:41 AM EDTOdyseey's OD-001 Shows Clinical Activity In Ulcerative Colitis, Advanced To Next Trial Stage(RTTNews) – Odyssey Therapeutics (ODTX) reported additional Phase 2a data supporting the clinical activity of OD-001, an oral treatment for ulcerative colitis, strengthening evidence for the drug's potential as the company prepares to advance the program into larger mid-stage stu
- RTTNews · Oct 20, 8:17 AM EDTOdyseey's OD-001 Meets Primary Goal In Ulcerative Colitis Study; Advances To Mid-Stage Trials(RTTNews) – Tuesday, Odyssey Therapeutics (ODTX) reported that its oral drug candidate OD-001 met the primary endpoint in a Phase 2a study in patients with moderate-to-severe ulcerative colitis, demonstrating a statistically significant improvement in disease activity after 12 we
- RTTNews · Oct 20, 7:50 AM EDTOdyssey Therapeutics Announces Encouraging Phase 2a Ulcerative Colitis Results(RTTNews) – Tuesday, Odyssey Therapeutics, Inc. (ODTX) announced data from the completed induction period of its Phase 2a clinical trial evaluating OD-001 in patients with moderate-to-severe ulcerative colitis.
- Fintel · Oct 9, 5:24 PM EDTRaymond James Initiates Coverage of Odyssey Therapeutics with OutperformFintel reports that on October 9, 2026, Raymond James initiated coverage of Odyssey Therapeutics (NASDAQCM:ODTX) with a Outperform recommendation.Prior to this coverage initiation, the stock closed at $18.12 on October 8, 2026. This pre-action close of $18.12 represents a price c
- RTTNews · Sep 7, 10:28 PM EDTBiotech Stocks At 52-Week Highs – PDEX +18% On FY'26 Results, ODTX +8%, EOLS, BFRI, DRTS(RTTNews) – The following biotech stocks reached a 52-week high on September 4, 2026, as various companies reported financial results and anticipated near-term clinical trial readouts.
- RTTNews · Aug 6, 11:37 AM EDTOdyssey Reports Wider Q2 Loss Of $52 Mln As OD-001 Advances In Phase 2 Studies(RTTNews) – Odyssey Therapeutics Inc. (ODTX), a clinical-stage biopharmaceutical company, on Tuesday announced financial results for the second quarter, and recorded a higher net loss due to increased spending on external Research and Development for the company's preclinical and
- RTTNews · Aug 6, 6:40 AM EDTEvotec Partners With Odyssey To Harness AI In Autoimmune Drug Discovery(RTTNews) – Evotec SE (EVO) announced that it has entered a strategic research and development collaboration with Odyssey Therapeutics, Inc, (ODTX) to accelerate discovery of new treatments for autoimmune and inflammatory diseases.
- RTTNews · Aug 6, 4:54 AM EDTBiotech Stocks At 52-Week Highs – BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.
- RTTNews · Jun 18, 8:43 AM EDTOdyssey Q1 Net Loss Narrows From Previous Year; Provides Upcoming Clinical Milestones(RTTNews) – Odyssey Therapeutics, Inc. (ODTX) reported on Wednesday its first quarter 2026 financial results and highlighted key clinical milestones.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Odyssey Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.